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Abstract
Background: The HMGA2 gene, coding for an architectural transcription factor involved in mesenchymal 
embryogenesis, is frequently deranged by translocation and/or amplification in mesenchymal tumours, generally 
leading to over-expression of shortened transcripts and a truncated protein.
Methods: To identify pathways that are affected by sarcoma-associated variants of HMGA2, we have over-expressed 
wild type and truncated HMGA2 protein in an immortalized mesenchymal stem-like cell (MSC) line, and investigated 
the localisation of these proteins and their effects on differentiation and gene expression patterns.
Results: Over-expression of both transgenes blocked adipogenic differentiation of these cells, and microarray analysis 
revealed clear changes in gene expression patterns, more pronounced for the truncated protein. Most of the genes 
that showed altered expression in the HMGA2-overexpressing cells fell into the group of NF-κB-target genes, 
suggesting a central role for HMGA2 in this pathway. Of particular interest was the pronounced up-regulation of SSX1, 
already implicated in mesenchymal oncogenesis and stem cell functions, only in cells expressing the truncated protein. 
Furthermore, over-expression of both HMGA2 forms was associated with a strong repression of the epithelial marker 
CD24, consistent with the reported low level of CD24 in cancer stem cells.
Conclusions: We conclude that the c-terminal part of HMGA2 has important functions at least in mesenchymal cells, 
and the changes in gene expression resulting from overexpressing a protein lacking this domain may add to the 
malignant potential of sarcomas.
Background
HMGA2 belongs to a family of nuclear proteins that con-
tain an N-terminal part that recognizes and binds to AT-
rich regions in the DNA [1] and an acidic C-terminal tail
that probably modulates their interactions with DNA [2],
and proteins [3]. HMGA proteins are not transactivators
on their own, but modulate the assembly of transcrip-
tional complexes at various levels [4-8], and may also reg-
ulate gene transcription through protein-protein
interactions without direct contact with DNA [9-11] or
by altering chromatin structure [12-16]. Interestingly, a
recent study suggested that both HMGA1 and HMGA2
are taking active parts in the formation of senescence-
associated heterochromatin foci and maintenance of the
growth-arrested state [17,18].
HMGA2 is expressed during embryonic development
while it is almost undetected in normal adult tissues
[19,20]. HMGA2 plays a critical role early in adipogene-
sis, probably by regulating the proliferation of preadipo-
cytes during differentiation [21], and mice lacking
functional HMGA2 protein exhibit a pygmy phenotype
with drastic reduction of adipose tissue [22]. On the other
hand, over-expression of a truncated HMGA2 protein
lacking the acidic C-terminal tail results in a giant pheno-
type with multiple lipomas [23,24].
Aberrations in the chromosomal region 12q14-15 that
affect HMGA2 are frequent in a variety of tumours. In
benign tumours of mesenchymal origin, HMGA2 is often
rearranged by translocation, and the resulting chimeric
transcripts are formed by fusion of the DNA-binding
domains, coded by exons 1-3, to ectopic sequences [25-
27]. In sarcomas, HMGA2 is frequently and selectively
amplified and rearranged [28]. We have cloned and
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Page 2 of 14sequenced a number of these cancer-associated ectopic
sequences from 12q as well as other chromosomes [29].
The only common factor that was found was the loss of
the 3'-untranslated region (UTR) as well as the last two
exons, resulting in fusion proteins containing as little as
one extra amino acid replacing the C-terminal part [29].
Recently it was shown that the HMGA2 3'-UTR con-
tains target sites for the let-7 miRNA, and thus the above
mentioned rearrangements lead to increased levels of
HMGA2 protein due to loss of miRNA-mediated repres-
sion [30,31]. Thus the attention has shifted from possible
oncogenic effects of loss of the acidic domain to effects of
increased expression, even of the wild type protein. Fur-
thermore, it turns out that the balance between let-7 and
HMGA2 governs the exit of cells from the undifferenti-
ated and self-renewing state, and HMGA2 is now thought
to be central in cancer in general [32-35]. Because
HMGA2 most frequently is rearranged in well-differenti-
ated liposarcomas, border-line tumours resembling adi-
pose tissue, most sarcoma cell lines, representing highly
malignant cancers with a different tissue type, would not
be appropriate to detect a phenotype when the gene is
over-expressed. We therefore chose an immature, stem-
like mesenchymal cell line with adipogenic potential to
investigate whether the wild type and truncated forms of
the protein activate the same pathways, by performing
gene expression analysis.
Methods
DNA constructs
The coding sequence and the part of the HMGA2 gene
encoding the DNA-binding domain (exon 1-3) were PCR-
amplified from pBluescript-HMGI-C [27] and cloned
into pEGFP-C3 (Clontech, Palo Alto, CA, USA) generat-
ing pEGFP-HMGA2WT and pEGFP-HMGA2TRUNC,
respectively.
Cell culture and stable transfectants
The human mesenchymal stem cell line (hMSC) trans-
duced with human telomerase reverse transcriptase
(hTERT), hMSC-TERT20 cells [36,37] were transfected
with the HMGA2 constructs described above, using
Fugene (Roche Diagnostics, Basel, Switzerland) according
to the manufacturer's protocol. Stable clones were
selected with 400 μg/ml G418 (Gibco BRL, Gaithersburg,
MD, USA) and clones with strong GFP-fluorescence were
established using fluorescence activated cell sorting. Cells
were maintained in RPMI1640 (Gibco) supplemented
with 10% fetal bovine serum and 100 μg/ml G418.
Fluorescence microscopy
Transfected hMSC-TERT20 cells grown on coverslips
were fixed with 10% formalin solution (Sigma-Aldrich, St.
Louis, MO, USA), permabilized with 0.1% Triton X-100
in PBS and blocked with 5% FCS. Staining for HMGA2
and B23 (nucleophosmin - a marker for the nuclear
matrix)[38] was performed using rabbit-anti HMGA2
(Strategic Diagnostics Inc., Newark, DE, USA), and
mouse-anti B23 followed by DyLight549-conjugated don-
key anti-rabbit and DyLight649-conjugated donkey anti-
mouse antibodies (Jackson Immunoresearch Laborato-
ries, West Grove, PA, USA), respectively. The samples
were mounted in Prolong Gold antifade reagent with
DAPI (Invitrogen, Carlsbad, CA, USA). The fluorescence
was visualized using a Zeiss LSM 510 confocal micro-
scope and pictures were taken of thin single plane sec-
tions.
Differentiation assay
The hMSC-TERT20 cells as described above, were
seeded at 10 000 cells/cm2 in medium supplemented with
a cocktail of 0.5 mM methylisobutylxanthine (Sigma-
Aldrich, St. Louis, MO, USA ), 1 μM dexamethasone
(Decadron™, MSD, Haarlem, Nederland), 2 μM insulin
(Sigma-Aldrich) and 20 μM Rosiglitazone (GlaxoSmith-
Kline, Harlow, UK) for 14 days. To monitor the differenti-
ation process, cultures were stained with Oil Red O
(Serva, Heidelberg, Germany). The stained neutral lipids
were extracted and the absorbance at 490 nm measured.
The number of cells was estimated by using SRB protein
assay on the same cultures. Briefly, proteins were precipi-
tated with 10% trichloracetic acid (Merck, Darmstadt,
Germany) and assayed by staining with sulforhodamine B
(Sigma-Aldrich), extraction and measuring the dye absor-
bance at 540 nm [39].
Northern blot analysis and quantitative RT-PCR
Total RNA was isolated from sub-confluent growing cells
using Trizol reagent (Invitrogen) according to the manu-
facturer's instructions. For Northern blot analysis, the
samples of RNA (10 μg) were run on a 1% formaldehyde
agarose gel, blotted onto a positively charged nylon mem-
brane and hybridizations were performed as described
[40]. Probes were sequentially hybridized to the mem-
brane and signals from an 18S rRNA oligonucleotide
were used to correct for unequal sample loading.
For quantitative RT-PCR, 0.5 μg of RNA from each
sample was reverse transcribed using the High-Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer's instructions. The
resulting cDNAs were used for real-time PCR using Taq-
Man Gene Expression Assays (Applied BioSystem; Addi-
tional file 1 Table S1). Threshold cycle (Ct) values were
measured and the comparative Ct method [41] was used
to calculate the log2- fold difference in transcript level of
the over-expressing cell lines relative to the parental. See
Additional file 1 Table S1 for probes.
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Cells were harvested and protein lysates were prepared by
sonicating cells resuspended in a nuclear lysis buffer of 50
mM Tris-HCl, pH 7.5, 0.1% SDS, 0.5 M NaCl, 1% NP-40,
1% DOC, 2 mM EDTA supplemented with protease
inhibitors (all from Sigma-Aldrich). 5 μg protein were
subjected to SDS-PAGE, transferred onto an Immobilon-
P membrane (Millipore, Billerica, MA, USA) and probed
with anti-HMGA2 (Santa Cruz Technologies, Santa
Cruz, CA, USA) and anti-tubulin (Santa Cruz). Second-
ary antibodies conjugated to horse radish peroxidase
(Dako, Glostrup, Denmark) were used according to the
manufacturer's instructions. Detection of antibody sig-
nals was performed with chemiluminescence using
SuperSignal West Dura Extended Duration Substrate
(Pierce, Rockford, IL, USA).
Microarray analysis
Total RNA was isolated from sub-confluent growing cells
using Trizol reagent according to the manufacturer's pro-
tocol and global expression analysis was performed on
HG-U133 Plus 2.0 oligonucleotide arrays (Affymetrix,
Santa Clara, CA, USA). Labelling, hybridisation and
scanning were performed at the Rikshospitalet University
of Oslo Microarray Core Facility http://microarray.rik-
shospitalet.no using standard conditions. As we aimed to
detect changes above the variation expected from differ-
ent sub-lines, i.e. above 3-fold, one array per sample was
sufficient (the technical variation between arrays being
much smaller).
Flow cytometry analysis of surface markers
To verify differential expression of CD24 and HLA-DR on
the cell surface, subconfluent growing cells were har-
vested, incubated with phycoerythrine-conjugated anti-
bodies and rinsed several times in PBS. IFNγ-treated cells
were cultured with 100 U/ml INFγ (Sigma) for 40 hours
prior to antibody staining. Antibody staining was
detected with a triple-focus DIVA flow cytometer (Bec-
ton Dickinson, Franklin Lakes, NJ, USA). Antibodies
used; anti-HLA-DR (Becton Dickinson); anti-CD24
(Beckman-Coulter, Fullerton, CA, USA). Data were ana-
lyzed with FlowJo software (Tree star, Ashland, Oregon,
USA).
Analysis of promoter sequences
Analysis of putative transcription factor binding sites was
performed using MatInspector http://www.genom-
atix.de/cgi-bin/matinspector/matinspector.pl and TESS
http://www.cbil.upenn.edu/tess/. The genomic DNA
sequences were retrieved from the Ensembl genome
browser http://www.ensembl.org/index.html covering
1500 base pairs of the 5' flanking regions (upstream from
the transcriptional start sites) and 500 base pairs down-
stream. A core similarity of at least 0.80 from MatInspec-
tor or TESS analysis was used as cut-off for potential
match to known transcription factor recognition
sequences.
Microarray data analysis
For GeneChip arrays, the raw intensity of individual sam-
ples was normalized using Bioconductor and the GC-
RMA algorithm http://www.bioconductor.org[42]. Nor-
malized gene expression levels for each transfected cell
line were compared with the parental cell line and probe
sets that exhibited less than 3-fold intensity change were
removed from further analysis. The remaining probe sets
were initially annotated according to entries in the
NetAffx database http://www.affymetrix.com. Using the
Database for Annotation, Visualization and Integrated
Discovery (DAVID located at http://apps1.niaid.nih.gov/
david[43], lists of differentially expressed genes, common
or specific for the samples, were analysed to identify
Gene Ontology (GO) terms that were significantly over-
represented using a modified Fisher Exact test (EASE-
score < 0.05). The redundancy in the annotations was
reduced by applying the clustering algorithm available in
DAVID using intermediate stringency and default set-
tings for the Kappa statistics.
Results
Exogenous HMGA2 is localized to the nucleus
To be able to monitor localization of the proteins, an
enhanced green fluorescence protein (eGFP) tag was
fused to the amino terminal end of both HMGA2 pro-
teins. Cells expressing eGFP-HMGA2WT or eGFP-
HMGA2TRUNC accumulate the eGFP-tagged proteins in
the nuclei, especially in DAPI-dense and nucleolar
regions (Fig. 1a), whereas eGFP alone showed general flu-
orescence throughout the cell, with lower level in nucleoli
than in the rest of the nuclei (not shown). Noteworthy,
both endogenous and fusion proteins co-localized with
DAPI-dense heterochromatin but they were also present
in numerous discrete foci that did not stain well by DAPI.
Moreover, both fusion proteins appeared to be enriched
in the nucleoli, detected by immunostaining against the
nuclear matrix marker nucleophosmin/B23 [38]. Immu-
nostaining for HMGA2, on the other hand, gave a more
even fluorescence also covering the nucleoli for both
endogeneous and ectopic HMGA2, and it is unclear
whether this indicates that the apparent nucleolar enrich-
ment of eGFP fusion proteins was a result of overexpres-
sion, or reduced nucleolar immunostaining could be due
to incomplete penetrance of antibodies into the nucleoli
compared to the efficient fluorescence from the fluores-
cent eGFP tags. Interestingly, endogenous HMGA2
seemed to be distributed throughout the granular region
in the nucleolus whereas the granular nucleophosmin/
B23 was restricted to the periphery. In addition, the
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Figure 1 Characterization of hMSC-TERT20 cells stably over-expressing eGFP-HMGA2WT and eGFP-HMGA2TRUNC. a) Nuclear localization of 
eGFP-tagged HMGA2 proteins was observed in hMSC-TERT20 over-expressing eGFP-HMGA2WT or eGFP-HMGA2TRUNC. Endogenous HMGA2 was visu-
alized by immunofluorescent staining with an anti-HMGA2 antibody (The intensity in parental cells was adjusted to make observation of nucleolar 
fluorescence possible). The nucleolus was detected with an anti-B23 antibody, while heterochromatin was stained by DAPI, showing co-localization 
of HMGA2 with both nucleoli and heterochromatin. Arrowheads show concentration of endogenous or eGFP-tagged HMGA2 at sites that correspond 
with nucleoli, while an arrow indicates discrete foci of HMGA2 within nucleoli. b) Expression levels of endogenous and exogenous HMGA2 transcripts; 
expected size of the endogenous transcript is 4468 bp, while the exogenous is only 327 bp due to the lack of the 3' UTR. Top panel, northern blot of 
HMGA2 mRNAs. Lower panel, quantitation of total HMGA2 mRNA levels by real-time PCR, normalized for TBP expression and represented as fold in-
duction over parental cells. c) Expression levels of endogenous and exogenous HMGA2 proteins, as detected on western blot. d) Accumulation of fat 
in cell cultures grown in basal medium supplemented with MDI and Rosiglitazone for 14 days. e) Relative accumulation of fat-bound Oil Red O after 
14 days of differentiation of hMSC-TERT20 cells. Data from two independent experiments are shown. Par, Parental cells; eGFP, eGFP-transduced; WT, 
transduced with eGFP-HMGA2WT; Trunc, transduced with eGFP-HMGA2TRUNC f) Expression of CD24 and HLA-DRA on each hMSC TERT20-derived cell 
lines as measured by flow cytometric mean fluorescence intensity (MFI).
Henriksen et al. BMC Cancer 2010, 10:329
http://www.biomedcentral.com/1471-2407/10/329
Page 5 of 14fusion proteins stayed bound to the condensed chromo-
somes during mitosis (data not shown).
The endogenous HMGA2 transcript and protein was
readily detected in hMSC-TERT20 cells (Fig. 1b and 1c),
and the ectopic transcript showed a lower steady-state
level than the endogenous transcript, as less than two-
fold increase of HMGA2 transcripts was measured by
quantitative PCR in the over-expressing cell lines. How-
ever, the levels of ectopically expressed protein was
increased several fold relative to endogenous HMGA2.
HMGA2 abolishes differentiation into the adipocytic 
lineage
Compared to the parental cells, forced expression of full-
length or truncated HMGA2 abolished the ability of the
cells to differentiate towards adipocytes and accumulate
fat (Fig. 1d). Noteworthy, the growth of the HMGA2-
overexpressing cells was unaffected by addition of differ-
entiation medium, whereas the proliferation of the paren-
tal cells was inhibited when differentiation was induced.
A control cell line expressing eGFP only showed growth
and differentiation patterns similar to the parental line
(i.e. within the variation expected when different pas-
sages of these cells was used, Fig 1d). The proliferation of
the different transfectants was indistinguish¬able from
that of the parental cells in the absence of differentiation
(not shown).
Identification of transcriptional targets
To find out how HMGA2 affects transcription, and possi-
ble effects of truncation, we analyzed the gene expression
profiles of proliferating cultures of the over-expressing
and the parental cell lines using the HG-U133 Plus 2.0
Affymetrix GeneChips. We identified 408 transcripts
that were up-regulated more than 3-fold relative to the
recipient cells in either of the two HMGA2-expressing
lines, while 477 transcripts were down-regulated more
than 3-fold. The microarray data were deposited in the
Array Express public database http://www.ebi.ac.uk/
microarray-as/ae/, accession number E-MEXP-2647),
and a list of the most differentially expressed genes is
shown in Table 1 (the complete list of transcripts changed
more than 3-fold is given in Additional file 2 Table S2).
Although the microarray technique can be used to detect
much smaller changes, we chose 3-fold as a level where
we would avoid smaller differences due to the prolonged
separate culturing of each transfectant line.
Interestingly, although both protein variants similarly
affected many genes, a large number of genes were differ-
ently affected. Out of 408 genes that showed up-regula-
tion, 66 genes were up regulated by both full-length and
truncated HMGA2. In addition, 84 and 258 were up-reg-
ulated in the cells expressing full-length and truncated
HMGA2 respectively. On the other hand, 139 genes were
down-regulated by both proteins while 99 and 239 were
down-regulated by full-length and truncated HMGA2
respectively. As the cells were analysed in their undiffer-
entiated state, we could not monitor genes directly
involved in differentiation. Although we detected no
change of the known HMGA2 target Imp2 (IGF2BP2)
[44] in this system, the about 2-fold down regulation by
both protein variants of both PPARα and PPARγ, central
regulators of adipogenesis, could contribute to the differ-
entiation block. In near all cases quantitative real-time
PCR (qPCR) analyses confirmed the direction of changes
in transcript levels observed by microarrays (Table 1). An
exception was members of the SSX gene family, which
were poorly distinguished by the microarray probes, and
of which only SSX1 was confirmed by real-time PCR.
Discrepant results were also found for LCP1, FGF1 and
HDAC9, which most likely were caused by alternative
splicing according to entries in the Alternative Splicing
and Transcript Diversity database http://www.ebi.ac.uk/
astd/main.html.
The over all correlation between microarray and real-
time ratios between HMGA2 transfectants and parental
cells was 0,96. The cells transfected with eGFP only were
included in the real-time validation as indicated in Table
1, and although there were some discrepancies, the over
all correlation between real-time ratios relative to the
eGFP-transfectants and those for the parental cells was
0.94, indicating their high degree of similarity.
Transcriptional effects common to wild type and truncated 
HMGA2
Sixty-six genes were up- and 139 genes were down-regu-
lated by both proteins. A large fraction of the affected
genes are known direct targets for NF-κB, and potential
intrinsic binding sites for HMGA proteins could be found
within many of the NF-κB sites (Additional file 3 Table
S3). Most of these genes code for proteins involved in
cytokine signalling. All of the genes in the CXC
chemokine cluster in chromosome band 4q13.3 that were
expressed in the parental cell line were down-regulated
by both protein variants. Other cytokines that were ini-
tially expressed in the parental cells and down-regulated
upon HMGA2 expression were IL1B, IL1RN, IL6, IL11,
IL15 and LIF1, all containing validated or predicted NF-
κB sites and only IL11 and IL15 lack intrinsic binding
sites for HMGA proteins. Several other possible NF-κB
targets were down regulated by the over-expression of
either form of HMGA2, e.g. THBS2, S100A4, IFI44L,
SOD2, PSMB9, IGFBP1, SERPINB1, NFKBIA, BDKRB1
and PTGES, all associated with increased NF-κB activity
(http://people.bu.edu/gilmore/nf-kb/target/index.html
and references therein). We also observed a four-fold
decrease of the primary microRNA miR-146A
(MIRN146A), which is known to be regulated by NF-κB
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showed down-regulation of several other potential NF-κB
target genes, such as BCL2A1, JUNB, LGALS3, HAS1,
TWIST1, PTGS2, CFLAR and BIC (encoding miR-155).
However, EDN1, MDK and TGM2, three genes thought
to be positively regulated by NF-κB [46-48], were strongly
up-regulated in both cell lines.
In addition, several putative interferon-responsive
genes were down-regulated, such as IFI27, IFITM1,
ISGF3G, AIM2, KYNU, C1S and OASL. Since the regula-
tory region of both IFI27 and IFITM1 contain IFN-α
stimulated response element (ISRE; Additional file 4
Table S4) that are recognized by the ISGF3 complex [49]
they work downstream of ISGF3G and are therefore
strongly dependent on the expression of the ISGF3G
gene. The ISGF3G gene itself is known to be regulated by
IL-6 [50] which indicates that these genes are secondary
targets to HMGA2.
Another large group of genes that showed expression
change was the Krüppel-type zinc finger proteins located
in several gene clusters mainly on the long arm of chro-
mosome 19 [51,52]. Some of these zinc finger proteins
contain a potent repressor domain, the Krüppel-associ-
ated box (KRAB), and they are likely involved in gene
silencing [53]. Interestingly, there was a broader up-regu-
lation of several other genes mapped to the chromosome
band 19q13 in the cell line over-expressing the truncated
HMGA2, including 35 Krüppel-type zinc finger genes of
which 27 contain a KRAB domain. This might indicate a
common regulatory mechanism for these genes that
could involve modulation of chromatin since there was
also an increased expression of several unrelated genes
near these clusters. Cells expressing HMGA2WT had an
increased expression of 12 Krüppel-type zinc finger
genes, nine of which mapped to the long arm of chromo-
some 19 and were up-regulated also in HMGA2TRUNC
transfectants. Six of the common up-regulated genes that
mapped to 19q contain a KRAB repressor domain, while
the three genes mapped to other chromosome regions,
showing elevated expression only in the cells expressing
HMGA2WT, all contain KRAB domains.
A gene ontology (GO) analysis revealed a highly signifi-
cant decrease in expression of genes encoding proteins
involved in signal transduction (p < 0.001) and response
to wounding (p < 0.001), mainly affecting genes involved
in cytokine-receptor signalling (p < 0.001), chemotaxis (p
< 0.001) and inflammatory response (p < 0.001). In addi-
tion, down-regulation of genes involved in regulation of
cellular proliferation (p = 0.0033) and epithelial cell dif-
ferentiation (p = 0.026) was observed. A few genes
involved in vascular development (p = 0.033) were up-
regulated. However, six out of 66 up-regulated genes
encode Krüppel-type zinc finger proteins containing a
KRAB repressor domain (p = 0.0051), indicating a com-
mon regulatory mechanism for these genes (Table 2).
Reciprocal effects of different forms of HMGA2
There were several genes up-regulated by HMGA2WT
and down- regulated in cells expressing the truncated
form, such as FGF13, EHF, HCLS1, MEST, G0S2 and
PTPRN2. Two of the gene products, G0S2 and MEST, are
both implicated in adipogenesis [54-56] while FGF13,
EHF, HCLS1 and PTPRN2 are potential regulators of
stem cell activity [57] , senescence [58], adhesion [59] and
insulin secretion [60], respectively.
Transcriptional effects specific to full-length HMGA2
Eighty-four genes were up-regulated and 99 genes were
down-regulated more than three-fold by wild-type but
not truncated HMGA2. Most genes were classified into
groups of more general GO terms providing limited
information about the underlying processes affected by
full-length HMGA2. However, a significant number of
the up-regulated genes are cell-type-specific genes
involved in embryonal development and likely reflect a
transition in the differentiation state of the cells. Some of
the down-regulated genes affect gene transcription.
However, most of the affected genes were poorly anno-
tated and gave little information about their cellular func-
tion.
Transcriptional effects specific to truncated HMGA2
Two hundred and fifty-eight genes were up-regulated and
239 genes were down-regulated in the cells expressing the
truncated protein. HMGA2TRUNC cells showed a clear
increase in expression of CXCL12 whereas the large
MHC class II gene cluster was down-regulated (Table
b1b). The down-regulation of the MHC class II gene
HLA-DRA was verified by qPCR (Table b1b) and using
flow cytometry, we could show that HLA-DRA was
expressed at a basal level on the surface of both the
parental cells and the cells over-expressing the wild type
HMGA2, but was strongly down-regulated in
HMGA2TRUNC cells in according with the expression data
(Fig. 1f). Adding interferon γincreased the expression of
HLA-DRA, resulting in a 40-fold increase in the level on
the HMGA2TRUNC cells, to give a level of surface protein
similar to that on the parental line (not shown).
Based on the microarray data, the SSX gene family
appeared to be co-induced in cells expressing
HMGA2TRUNC, but real-time PCR was only able to verify
the induction of SSX1 transcripts. Interesting, the expres-
sion increased by 1000-fold indicating a specific activa-
tion of this gene.
The GO analysis revealed a significant down-regulation
of genes involved in antigen presentation and processing
(p < 0.001), and organism development (p = 0.0021). A
Henriksen et al. BMC Cancer 2010, 10:329
http://www.biomedcentral.com/1471-2407/10/329
Page 9 of 14
Table 2: Functional annotation analysis of differentially expressed genes
Biological processes affected by over-expression of wild type and truncated HMGA2
Vascular development (4 of 66 up-regulated genes) p = 0.039
Response to wounding (17 of 139 down-regulated genes) p < 0.001
Signal transduction (40/139) p < 0.001
Chemotaxis (11/139) p < 0.001
Cytosolic calcium ion homeostasis (5/139) p < 0.001
Phosphate transport (5/139) p = 0.0017
Regulation of cell proliferation (11/139) p = 0.0033
Cell migration (8/139) p = 0.0057
Cell recognition (3/139) p = 0.027
Epithelial cell differentiation (3/139) p = 0.026
Wound healing (4/139) p = 0.042
Biological processes affected by over-expression of wild type HMGA2
Multi-cellular organismal development (20 of 84 up-regulated genes) p = 0.0011
Response to hormone stimulus (4/84) p = 0.0034
Regulation of signal transduction (7/84) p = 0.022
Pyridine nucleotide biosynthetic process (3 of 99 down-regulated genes) p = 0.0017
Steroid hormone receptor activity (3/99) p = 0.0032
Negative regulation of transcription factor activity (3/99) p = 0.0034
Positive regulation of transcription (7/99) p = 0.0065
Response to external stimulus (8/99) p = 0.042
Biological processes affected by over-expression of truncated HMGA2
Regulation of transcription (61 of 258 up-regulated genes) p < 0.001
Intracellular protein transport across a membrane (6/258) p = 0.0032
Membrane organization and biogenesis (11/258) p = 0.011
Ras protein signaling transduction (9/258) p = 0.031
Regulation of cytoskeleton organization and biogenesis (4/258) p = 0.042
Antigen processing and presentation (10 of 239 down-regulated genes) p < 0.001
Multi-cellular organismal development (41/239) p = 0.0021
Cell adhesion (16/239) p = 0.019
Eye morphogenesis (3/239) p = 0.035
The genes were classified into biological processes using gene ontology terms. Each biological process was determined if it was significantly 
over- or underrepresented (p < 0.05) by comparing the observed frequency of genes to the expected frequency of genes on the Affymetrix 
GeneChip that cover 50 547 known genes. Significantly over- or under-represented processes were grouped and ranked according to the 
geometric mean of their p-values. A representative annotation term for each cluster, the number of genes associated with the term and its 
p-value was listed.
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teins with roles in regulation of transcription (p < 0.001)
and most of them were KRAB-zinc finger proteins. In
addition, genes encoding proteins involved in intracellu-
lar protein transport across membranes (p = 0.0032),
organization of cytoskeletal structures (p = 0.042) and
Ras signalling (p = 0.031), were significant up-regulated.
Discussion
The deregulation of expression caused by the absence of
the 3'-UTR in our transgenes, and thus loss of let-7--
mediated inhibition, resulted in abundant expression of
HMGA2 protein (Fig. 1c). The eGFP fusion proteins were
shown to localise in the nucleus just like the endogenous
protein. Their distribution to the nucleoli (Fig. 1a, arrow-
heads) was unexpected though HMGA2 has previously
been found to interact with the mainly nucleolar nucleo-
phosmin/B23 protein [61]. Furthermore, the localization
of endogenous HMGA2 in the nucleoli was clearly
restricted to numerous discrete foci (Fig. 1a, arrow). The
distribution of these sites was occasionally scattered
throughout the nucleolus or more often restricted to the
periphery of the nucleolar body were they seemingly co-
localized with B23. In this outer part of nucleolus the late
processing of rRNAs takes place before they assemble
into ribosomal subunits [62], suggesting that HMGA2
might be involved in these processes. However, this could
also be a result of B23 acting as a molecular chaperone
[63], sequestering HMGA2 to the nucleolus, as described
for IRF-1 [64], pRb [65] and TRF2 [66].
Both wild type and truncated HMGA2 abrogated
growth inhibition and adipogenesis (Fig. 1d), probably by
a common mechanism. It appears that both HMGA2 pro-
teins prevented the growth arrest necessary for adipo-
genic differentiation, as cellular protein accumulated at
the same rate as in un-induced cells. Interestingly, a
recent study showed that the level of HMGA2 is highly
regulated during adipogenesis by let-7 and knockdown of
HMGA2 by this miRNA inhibited both clonal expansion
and the transition to terminal differentiation [67].
HMGA2 seems to act in a narrow window early in the
adipogenesis where it is involved in expanding the popu-
lation of preadipocytes and keeps the cells in an undiffer-
entiated state. This would be consistent with our HMGA2
over-expressing keeping the mesenchymal stem-like cells
in a proliferative state, preventing differentiation into adi-
pocytes. Transgenic mice overexpressing truncated
HMGA2 gene, on the other hand, develop well differenti-
ated lipomas and abundant adipose tissue [24]. This dis-
crepancy is not surprising, as the conditions during
culture in vitro and development in vivo are very differ-
ent, among other things due to the micro¬environment.
Furthermore, the absence in hMSC- TERT20 cells of p16,
encoded by the INK4A/ARF locus, and possibly other
oncogenic alterations in our model system [37] may be
expected to contribute to the results, although this block-
age of differentiation was confirmed in preliminary
experiments using another, non-tumourigenic telom-
erase-immortalised MSC line (Stabell et al, unpublished).
It has recently been reported that HMGA2 represses
transcription of INK4A/ARF [68] and suggested that this
might be mediated through JUNB, a transactivator of
INK4A/ARF [69]. Consistent with previous findings
[3,68], both HMGA2 forms down-regulated the expres-
sion of NF-κB regulated genes in the cells, and in addition
to binding sites for NF-κB, many of the down-regulated
genes identified here, including JUNB, also contain
potential intrinsic binding sites for HMGA2 (Additional
file 3 Table S3). These findings suggest that HMGA2 may
repress JUNB by interfering with the NF-κB mediated
transactivation of this gene. However, since the INK4A/
ARF locus is deleted in our cell model, we were not able
to confirm an effect on this gene by over-expressing
HMGA2. One might speculate that the higher number of
genes affected by the truncated protein could be due to a
regulatory or moderating function of the c-terminal
domain, but this remains to be investigated further.
In spite of abnormal dynamics of growth and differenti-
ation of our model system, we expect the transcription
response to HMGA2 overexpression to reflect authentic
regulatory functions in an immature mesenchymal con-
text, as these cells show differentiation properties similar
to primary mesenchymal stem-like cell cultures.
HMGA2 is known to participate in the formation of
heterochromatin in senescent cells [18] and we found
that both full-length and truncated HMGA2 proteins co-
localized extensively with DAPI-dense regions, probably
enriched in heterochromatin (Fig. 1a). The modulation of
chromatin by HMGA2 could also be responsible for the
coordinated induction of the chromosome 19 KRAB-
ZNF genes. Several members of this family modulate cell
growth and survival, and they are implicated in malignant
disorders [70], although the functions of most of them are
largely unknown. Noteworthy, a recently study showed
that Apak, encoded by the ZNF420 gene, repress p53-
mediated apoptosis [71] and it was suggested that various
KRAB-type zinc-finger proteins may modulate p53 activ-
ity. Although the level of ZNF420 transcript increased
more than two-fold in cells over-expressing HMGA2, no
effects on pro-apoptotic genes were observed (data not
shown).
Interestingly, our most up-regulated gene, SSX1,
encodes a protein that also is involved in chromatin mod-
ulation, and is already involved in sarcoma oncogenesis
[72]. Members of this gene family are seen expressed in
germ cells and mesenchymal stem cells, decrease upon
differentiation into adipocytes and osteocytes [73,74],
and are expressed in various tumor types [75]. SSX pro-
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the nucleus and likely act through these chromatin regu-
lators to maintain repression of target genes [76,77]. This
could suggest that they play a key role in maintaining
mesenchymal cell stemness [78], and that increased SSX1
expression could reflect a cancer stem cell phenotype.
Although the SSX gene family is highly conserved, the
variable activation of SSX genes reported in malignant
cells [74] suggests gene-specific transcription control.
Their restricted expression pattern is mainly governed by
epigenetic silencing [79,80], which could be affected by
HMGA2TRUNC. An AT-rich region 1 kb upstream from
transcription start of SSX1 contains a likely binding site
for HMGA2 (-1076 TATTAATAT), although it remains to
be proven that it binds specifically to HMGA2TRUNC.
Recent findings suggest that both HMGA2 [81] and SSX
proteins [73,82] are taking part in the epithelial mesen-
chymal transition, where epithelial cells convert to motile
mesenchymal cells [83]. However, the significance of
these processes in already mesenchymal cells is unclear.
Interestingly, we observed a change in both cell lines to a
more restricted but still mesenchymal phenotype by the
repression of some epithelial markers, such as keratin 14
(KRT14) and the P selectin ligand CD24, and up-regula-
tion of mesenchymal-specific genes such as CD44, proba-
bly shifting from a multi-lineage potential [84] to a more
restricted but proliferative state. The down-regulation of
the NF-κB pathway might signify an undifferentiated
mesenchymal phenotype committed to adipogenic lin-
eage depending on further signalling cues.
The induction of CXCL12 gene expression by
HMGA2TRUNC is probably the cause of down-regulation
of HLA-DRA and other major histocompatibility com-
plex class II (MHC-II) proteins on the cell surface, due to
this cytokine's ability to repress the class II transactivator
[85]. The fact that interferon induced HLA-DRA protein
levels to a similar level in parental and HMGA2TRUNC
cells supports this interpretation. Loss of MHC-II expres-
sion in lymphomas correlates with poor survival [86], and
absence of HLA-DR expression is seen in other cancers
[87]. Their lost ability to present tumor antigens on their
cell surfaces may contribute to their escape from immu-
nosurveillance and therefore this might also provide a
selective advantage to sarcoma cells expressing truncated
HMGA2.
Since HMGA2 truncation and amplification is
observed initially in the development of well-differenti-
ated liposarcomas, borderline tumours of adipocytic dif-
ferentiation, and always in combination with
amplification of the p53-blocking MDM2, we do not
expect a very "malignant" phenotype when HMGA2 is
overexpressed on its own. On the other hand, a pheno-
type where adipogenesis is inhibited would be consistent
with a role in adipogenic tumours. When truncated
HMGA2 is overexpressed in transgenic mice, they
develop adipose hypertrophy, which indicates that adipo-
cytic differentiation is not completely blocked [24]. Like
our constructs, theirs lack the 3' UTR, thus preventing
down regulation of HMGA2 by let-7 as differentiation
progresses, and the most likely explanation for the dis-
crepancy is that the balance of proliferation and differen-
tiation over weeks or months in vivo is sufficiently
different for our short-term in vitro conditions, or there
are differences in how human and mouse cells are regu-
lated at this level. Although we get the same result in
another non-transformed hMSC line, this model is also
based on ectopic activation of telomerase, which could
affect the result[88,89].
To investigate these questions, we will determine the
activity of truncated HMGA2 in sarcoma cells by siRNA-
based knock-down in cells with the natural malignant
genetic background.
Conclusions
Our results show that over-expression of truncated
HMGA2 induces a more mesenchymal (stem-like) phe-
notype, characterized by resistance toward differentia-
tion, over-expression of SSX1, lost expression of certain
epithelial markers and strengthened expression of mes-
enchymal markers. We suggest that amplification and
truncation of HMGA2 in sarcoma provide the tumors
with a more stem-like phenotype.
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